Avidity Partners Management LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Avidity Partners Management LP reported 61 stock positions worth $1.0 billion. Its top holding was Dianthus Therapeutics (DNTH) at 6.2% of the portfolio, followed by Boston Scientific (BSX, 4.6%) and Janux Therapeutics (JANX, 4.0%). Compared with Q3 2024, it opened 4 new positions, sold out of 24, added to 6 and reduced 46. The biggest buy was Janux Therapeutics (JANX, shares +32%) and the biggest sale Perspective Therapeutics (CATX, shares −22%).
- Most Recent 13F
- Q2 2026
- Location
- DALLAS, TX
- CIK
- 0001791827
- Portfolio Value
- $1.0B (Q4 2024)
- SEC Filing
- 0001791827-25-000002 ↗ filed Feb 14, 2025
Holdings Value
Holdings 61 stocks · $1.0B
| DNTH Dianthus Therapeutics Inc. | 6.24% | 2,873,000 | $62.6M | Reduce -1.5% |
| BSX Boston Scientific Corp. | 4.59% | 515,000 | $46.0M | Reduce -46.5% |
| JANX Janux Therapeutics Inc. | 3.96% | 741,900 | $39.7M | Add +32.0% |
| NTRA Natera Inc. | 3.53% | 223,800 | $35.4M | Reduce -59.8% |
| EXAS Exact Sciences Corp. | 3.38% | 603,011 | $33.9M | Add +2.5% |
| ISRG Intuitive Surgical Inc. | 3.37% | 64,800 | $33.8M | Reduce -56.3% |
| CGON CG Oncology Inc. | 3.14% | 1,097,800 | $31.5M | Reduce -33.7% |
| UNH Unitedhealth Group Inc. | 3.03% | 60,000 | $30.4M | Reduce -31.4% |
| NBIX Neurocrine Biosciences Inc. | 3.00% | 220,400 | $30.1M | Reduce -52.1% |
| IDYA Ideaya Biosciences Inc. | 2.89% | 1,126,700 | $29.0M | Reduce -17.9% |
| JAZZ Jazz Pharmaceuticals PLC | 2.88% | 234,500 | $28.9M | Reduce -45.6% |
| MIRM Mirum Pharmaceuticals Inc. | 2.75% | 666,200 | $27.5M | Reduce -8.9% |
| ACHC Acadia Healthcare Co. Inc. | 2.60% | 658,000 | $26.1M | Reduce -33.2% |
| ARVN Arvinas Inc. | 2.60% | 1,358,000 | $26.0M | Reduce -9.3% |
| GKOS Glaukos Corp. | 2.54% | 170,000 | $25.5M | Reduce -50.7% |
| DXCM Dexcom Inc. | 2.47% | 318,000 | $24.7M | Add +32.5% |
| TMO Thermo Fisher Scientific Inc. | 2.31% | 44,600 | $23.2M | Reduce -35.0% |
| HUM Humana Inc. | 2.26% | 89,200 | $22.6M | Reduce -31.2% |
| KYMR Kymera Therapeutics Inc. | 2.01% | 500,000 | $20.1M | No change |
| AVTR Avantor Inc. | 1.99% | 947,000 | $20.0M | Reduce -23.3% |
| SNDX Syndax Pharmaceuticals Inc. | 1.98% | 1,500,000 | $19.8M | Reduce -38.9% |
| CNTA Centessa Pharmaceuticals Ltd. | 1.95% | 1,165,800 | $19.5M | Reduce -45.3% |
| RVMD Revolution Medicines Inc. | 1.95% | 446,200 | $19.5M | Reduce -43.5% |
| XENE Xenon Pharmaceuticals Inc. | 1.85% | 474,000 | $18.6M | Reduce -42.0% |
| THC Tenet Healthcare Corp. | 1.72% | 137,000 | $17.3M | Reduce -45.9% |
| INSM Insmed Inc. | 1.60% | 232,800 | $16.1M | Reduce -60.7% |
| AXSM Axsome Therapeutics Inc. | 1.59% | 188,000 | $15.9M | Reduce -36.5% |
| BPMC Blueprint Medicines Corp. | 1.54% | 176,600 | $15.4M | Reduce -43.9% |
| DHR Danaher Corp. | 1.53% | 67,000 | $15.4M | Reduce -29.5% |
| RARE Ultragenyx Pharmaceutical Inc. | 1.48% | 352,000 | $14.8M | Reduce -53.2% |
| ILMN Illumina Inc. | 1.46% | 109,700 | $14.7M | Reduce -62.4% |
| ABBV Abbvie Inc. | 1.43% | 80,700 | $14.3M | Reduce -19.3% |
| RCKT Rocket Pharmaceuticals Inc. | 1.32% | 1,053,300 | $13.2M | Add +40.6% |
| BMY Bristol-Myers Squibb Co. | 1.21% | 215,000 | $12.2M | Reduce -18.3% |
| TMDX Transmedics Group Inc. | 1.20% | 192,400 | $12.0M | Add +597.1% |
| PHAT Phathom Pharmaceuticals Inc. | 1.13% | 1,390,100 | $11.3M | Reduce -23.0% |
| SGRY Surgery Partners Inc. | 1.09% | 514,200 | $10.9M | Reduce -37.8% |
| ORIC Oric Pharmaceuticals Inc. | 1.02% | 1,265,200 | $10.2M | Reduce -12.6% |
| NAMS Newamsterdam Pharma Co. NV | 0.91% | 354,000 | $9.1M | Reduce -60.2% |
| INCY Incyte Corp. | 0.89% | 129,600 | $9.0M | Reduce -57.9% |
| CATX Perspective Therapeutics Inc. | 0.86% | 2,694,600 | $8.6M | Reduce -21.8% |
| ASND Ascendis Pharma A/S | 0.85% | 62,000 | $8.5M | Reduce -47.9% |
| BHVN Biohaven Ltd. | 0.83% | 222,900 | $8.3M | Reduce -52.1% |
| ITCI Intra-Cellular Therapies Inc. | 0.81% | 97,000 | $8.1M | Reduce -58.4% |
| IMUX Immunic Inc. | 0.79% | 7,966,400 | $8.0M | Reduce -3.6% |
| CNTX Context Therapeutics Inc. | 0.78% | 7,477,200 | $7.9M | Add +0.8% |
| ORKA Oruka Therapeutics Inc. | 0.68% | 352,124 | $6.8M | Reduce -55.5% |
| REGN Regeneron Pharmaceuticals | 0.60% | 8,400 | $6.0M | New |
| BRKR Bruker Corp. | 0.45% | 76,300 | $4.5M | New |
| VERA Vera Therapeutics Inc. | 0.42% | 100,000 | $4.2M | New |
| RGNX Regenxbio Inc. | 0.41% | 532,000 | $4.1M | Reduce -53.0% |
| QURE Uniqure NV | 0.39% | 222,000 | $3.9M | Reduce -67.0% |
| KZR Kezar Life Sciences Inc. | 0.34% | 502,600 | $3.4M | No change |
| KROS Keros Therapeutics Inc. | 0.33% | 210,000 | $3.3M | Reduce -28.4% |
| AKRO Akero Therapeutics Inc. | 0.23% | 82,000 | $2.3M | New |
| DYN Dyne Therapeutics Inc. | 0.23% | 96,000 | $2.3M | Reduce -41.8% |
| COGT Cogent Biosciences Inc. | 0.22% | 287,104 | $2.2M | Reduce -71.3% |
| SCYX Scynexis Inc. | 0.15% | 1,228,910 | $1.5M | Reduce -15.2% |
| KPTI Karyopharm Therapeutics Inc. | 0.14% | 2,018,500 | $1.4M | No change |
| HYPR Hyperfine Inc. | 0.10% | 1,188,178 | $1.0M | No change |
| BLUEBIRD BIO INC | 0.07% | 81,555 | $680K | No change |
Options reported separately and not counted above: ARVN calls ($13.4M), NMRA calls ($1.6M).
Portfolio Sells Q3 2024 → Q4 2024
| CATX Perspective Therapeutics Inc. | Reduce -21.8% | 0.86% | −1.49 |
| NMRA Neumora Therapeutics Inc. | Sold out | 0.00% | −1.21 |
| BMRN Biomarin Pharmaceutical Inc. | Sold out | 0.00% | −1.15 |
| ARGX Argenx SE - ADR | Sold out | 0.00% | −1.06 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.96 |
| NGNE Neurogene Inc. | Sold out | 0.00% | −0.91 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −0.91 |
| BNTX Biontech SE-ADR | Sold out | 0.00% | −0.88 |
| ZTS Zoetis Inc. | Sold out | 0.00% | −0.71 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -53.2% | 1.48% | −0.65 |
| IMNM Immunome Inc. | Sold out | 0.00% | −0.65 |
| INSM Insmed Inc. | Reduce -60.7% | 1.60% | −0.60 |
| ACHC Acadia Healthcare Co. Inc. | Reduce -33.2% | 2.60% | −0.59 |
| PHAT Phathom Pharmaceuticals Inc. | Reduce -23.0% | 1.13% | −0.54 |
| KROS Keros Therapeutics Inc. | Reduce -28.4% | 0.33% | −0.54 |
| ILMN Illumina Inc. | Reduce -62.4% | 1.46% | −0.48 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −0.46 |
| SNDX Syndax Pharmaceuticals Inc. | Reduce -38.9% | 1.98% | −0.43 |
| PRVA Privia Health Group Inc. | Sold out | 0.00% | −0.43 |
| THC Tenet Healthcare Corp. | Reduce -45.9% | 1.72% | −0.42 |
| HELP Cybin Inc. | Sold out | 0.00% | −0.42 |
| ESTA Establishment Labs Holdings | Sold out | 0.00% | −0.37 |
| CGEM Cullinan Therapeutics Inc. | Sold out | 0.00% | −0.36 |
| BHVN Biohaven Ltd. | Reduce -52.1% | 0.83% | −0.36 |
| ISRG Intuitive Surgical Inc. | Reduce -56.3% | 3.37% | −0.34 |
| COGT Cogent Biosciences Inc. | Reduce -71.3% | 0.22% | −0.33 |
| IMCR Immunocore Holdings PLC-ADR | Sold out | 0.00% | −0.32 |
| ORKA Oruka Therapeutics Inc. | Reduce -55.5% | 0.68% | −0.31 |
| SNY Sanofi-ADR | Sold out | 0.00% | −0.29 |
| SGRY Surgery Partners Inc. | Reduce -37.8% | 1.09% | −0.28 |
| EDIT Editas Medicine Inc. | Sold out | 0.00% | −0.25 |
| RGNX Regenxbio Inc. | Reduce -53.0% | 0.41% | −0.20 |
| INCY Incyte Corp. | Reduce -57.9% | 0.89% | −0.15 |
| IMVT Immunovant Inc. | Sold out | 0.00% | −0.14 |
| ANRO Alto Neuroscience Inc. | Sold out | 0.00% | −0.14 |
| PRME Prime Medicine Inc. | Sold out | 0.00% | −0.14 |
| SYRS Syros Pharmaceuticals Inc. | Sold out | 0.00% | −0.12 |
| TIL Instil Bio Inc. | Sold out | 0.00% | −0.10 |
| PRLD Prelude Therapeutics Inc. | Sold out | 0.00% | −0.09 |
| DYN Dyne Therapeutics Inc. | Reduce -41.8% | 0.23% | −0.08 |
| NTRA Natera Inc. | Reduce -59.8% | 3.53% | −0.07 |
| ITCI Intra-Cellular Therapies Inc. | Reduce -58.4% | 0.81% | −0.06 |
| ASND Ascendis Pharma A/S | Reduce -47.9% | 0.85% | −0.06 |
| CGON CG Oncology Inc. | Reduce -33.7% | 3.14% | −0.05 |
| CMAXQ Caremax Inc. | Sold out | 0.00% | −0.00 |
| SCYX Scynexis Inc. | Reduce -15.2% | 0.15% | +0.04 |
| BPMC Blueprint Medicines Corp. | Reduce -43.9% | 1.54% | +0.05 |
| IMUX Immunic Inc. | Reduce -3.6% | 0.79% | +0.10 |
| RVMD Revolution Medicines Inc. | Reduce -43.5% | 1.95% | +0.12 |
| TMO Thermo Fisher Scientific Inc. | Reduce -35.0% | 2.31% | +0.15 |
Portfolio Buys Q3 2024 → Q4 2024
| JANX Janux Therapeutics Inc. | Add +32.0% | 3.96% | +2.66 |
| DXCM Dexcom Inc. | Add +32.5% | 2.47% | +1.64 |
| EXAS Exact Sciences Corp. | Add +2.5% | 3.38% | +1.33 |
| TMDX Transmedics Group Inc. | Add +597.1% | 1.20% | +0.97 |
| RCKT Rocket Pharmaceuticals Inc. | Add +40.6% | 1.32% | +0.61 |
| REGN Regeneron Pharmaceuticals | New | 0.60% | +0.60 |
| BRKR Bruker Corp. | New | 0.45% | +0.45 |
| VERA Vera Therapeutics Inc. | New | 0.42% | +0.42 |
| AKRO Akero Therapeutics Inc. | New | 0.23% | +0.23 |
| CNTX Context Therapeutics Inc. | Add +0.8% | 0.78% | +0.04 |
Options Activity Q3 2024 → Q4 2024
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 45 | $624.4M | DNTH, CGON, ORKA, JBIO, ELVN |
| Q1 2026Amended | 45 | $493.8M | DNTH, CGON, ORKA, CATX, JBIO |
| Q4 2025 | 39 | $346.7M | DNTH, CGON, JBIO, ORKA, TEVA |
| Q3 2025 | 43 | $439.4M | DNTH, CGON, MDT, BSX, ORKA |
| Q2 2025 | 55 | $498.8M | CGON, BSX, NTRA, DNTH, EXAS |
| Q1 2025 | 63 | $484.9M | BSX, DNTH, UNH, CGON, HUM |
| Q4 2024 | 61 | $1.0B | DNTH, BSX, JANX, NTRA, EXAS |
| Q3 2024 | 81 | $2.0B | BSX, DNTH, ISRG, NTRA, CGON |
| Q2 2024 | 84 | $2.4B | ISRG, BSX, NTRA, ARVN, ACHC |
| Q1 2024 | 86 | $2.8B | FUSN, BSX, ARVN, ISRG, DNTH |